(NASDAQ: INDP) Indaptus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.32%.
Indaptus Therapeutics's earnings in 2026 is -$18,857,556.On average, 3 Wall Street analysts forecast INDP's earnings for 2026 to be -$742,711,106, with the lowest INDP earnings forecast at -$713,585,180, and the highest INDP earnings forecast at -$764,555,550. On average, 3 Wall Street analysts forecast INDP's earnings for 2027 to be -$517,472,124, with the lowest INDP earnings forecast at -$497,179,099, and the highest INDP earnings forecast at -$532,691,892.
In 2028, INDP is forecast to generate $91,250,665 in earnings, with the lowest earnings forecast at $87,672,207 and the highest earnings forecast at $93,934,508.